[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligometastatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligometastatic-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100642127","mr-guided-single-fraction-sbrt-for-nodal-oligorecurrent-prostate-cancer-pinpoint-100642127",false,"NCT07635108","MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)","Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer","PINPOINT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed informed consent\n* Histologically proven initial diagnosis of adenocarcinoma of the prostate\n* ECOG performance status 0-2\n* Biochemical recurrence after curatively intended local treatment (radical prostatectomy and\u002For radiotherapy), with PSMA-PET\u002FCT-verified nodal relapse in the pelvis or abdomen\n* Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment\n* Life expectancy \\> 6 months\n* Lymph node size ≤ 2 cm\n\nExclusion Criteria:\n\n* Medical contraindications to MRI\n* Inability to tolerate the physical set-up required for SABR\n* Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury\n* Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)\n* Uncontrolled intercurrent illness","MALE","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"NA","This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative treatment. Participants receive one fraction of 24 Gy delivered with MR-guided stereotactic body radiotherapy (SBRT), which uses MRI to visualise the tumour and surrounding organs during treatment. The main goal is to assess safety (severe side effects). The trial also evaluates local tumour control, longer-term side effects, time until hormone (androgen deprivation) therapy is needed, survival, and quality of life. The trial aims to enrol 48 patients.",[27,28,29,30],"Prostate Cancer","Oligo-metastatic Prostate Carcinoma","Oligometastatic Cancer","Nodal Oligorecurrent Prostate Cancer",[32,33,34,35,36,37,38,39,40,41,42],"Single-fraction SBRT","Nodal oligorecurrent prostate cancer","MR-guided SBRT","MR-Linac","Stereotactic body radiotherapy","Stereotactic ablative radiotherapy","Single-fraction radiotherapy","Oligometastasis \u002F oligorecurrence","Metastasis-directed therapy","PSMA-PET\u002FCT","Lymph node metastasis","NOT_YET_RECRUITING","2026-06-11",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":21},"2026-06-01",{"date":51,"type":21},"2035-09",{"name":53,"class":54},"Odense University Hospital","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":55},"100625716","clinical-utility-of-ctdna-in-the-treatment-of-oligometastatic-disease-100625716","NCT07426250","Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease","Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease - A Prospective Observational Clinical Study - A Part of the POB-project","Inclusion Criteria:\n\n* Metastatic spread from histopathological diagnosed solid cancer\n* Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)\n* ≥ 18 years\n* Written and oral consent\n\nExclusion Criteria:\n\n* Other cancer disease within 5 years\n* Conditions that will contraindicate blood samples","ALL",{"count":65,"type":21},500,"OBSERVATIONAL","This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.",[29],[70],"Local Ablative Treatment of Oligometastatic Disease","2026-02-16",{"date":73,"type":47},"2026-02-23",{"date":75,"type":21},"2026-03-01",{"date":77,"type":21},"2030-09-01",{"name":79,"class":54},"Aarhus University Hospital"]